Jan. 12, 2023 – HVR Cardio, a clinical-stage medical technology business creating Structural Heart cardiovascular solutions for transcatheter mitral valve replacement, announced today the completion of its 10.7 million Euro ($11.1 million US) Series B fundraising round. Innovestor Life Science Fund and Tesi, based in Finland, led this Series B round.
With its CathHELIXTM Annuloplasty System, HVR Cardio is developing a breakthrough technique for transcatheter mitral valve repair for use by Structural Heart Physicians to treat mitral regurgitation (MR). “I joined the team because of the promise of this unique technology,” stated Tom Fleming, CEO of HVR Cardio. “This money allows us to take the next step into human clinical studies and grow our staff.” HVR Cardio’s novel Helix ring technology is intended to be a simple, safe, and secure transcatheter annuloplasty treatment that allows MR reduction without anchoring the native leaflets.
At the same time, HVR Cardio announced the appointment of its new leadership team, which includes:
- Tom Fleming, who joined HVR Cardio as Chief Executive Officer in May 2022, brings with him 21 years of experience at Boston Scientific, where he most recently served as VP and GM for its Structural Heart Valve Business. Fleming formerly served as CEO of 4Tech Inc.
- Tim Girton joins as Chief Technology Officer in July 2022, bringing with him 23 years of experience at Boston Scientific, most recently as VP of Research and Development, Interventional Cardiology.
With its CathHELIXTM Annuloplasty System, HVR Cardio is developing a breakthrough technique for transcatheter mitral valve repair for use by Structural Heart Physicians to treat mitral regurgitation (MR). “I joined the team because of the promise of this unique technology,” stated Tom Fleming, CEO of HVR Cardio. “This money allows us to take the next step into human clinical studies and grow our staff.” HVR Cardio’s novel Helix ring technology is intended to be a simple, safe, and secure transcatheter annuloplasty treatment that allows MR reduction without anchoring the native leaflets.
“MR is a prevalent valvular heart disease that affects millions of individuals and leaves a tremendous demand for improved treatment alternatives. We are enthusiastic about the elegant and minimally invasive CathHELIXTM technology, which will give patients fresh hope, “Pekka Simula, Partner at Innovestor Life Science, adds.
HVR Cardio is a Finnish cardiovascular device firm developing novel mitral valve repair treatments based on its unique helix technology. Its goal is to provide faster, easier-to-use, and less intrusive solutions while maintaining clinical efficacy.
We try our best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by! Next Article
 Series B fundraising round. Innovestor Life Science Fund and Tesi, based in Finland, led this Series B round.){kind=link}